Free Trial

Rhythm Pharmaceuticals (RYTM) Earnings Date, Estimates & Call Transcripts

Rhythm Pharmaceuticals logo
$56.23 -3.54 (-5.92%)
(As of 11/15/2024 ET)

Rhythm Pharmaceuticals Latest Earnings Summary

Upcoming Q4
Earnings Date
Feb. 27Estimated
Actual EPS
(Nov. 5)
-$0.73 Beat By $0.07
Consensus EPS
(Nov. 5)
-$0.80

Rhythm Pharmaceuticals announced Q3 2024 earnings on November 5, 2024, reporting an EPS of -$0.73, which beat analysts' consensus estimates of -$0.80 by $0.07. Quarterly revenue rose 47.6% year-over-year to $33.20 million, above analyst estimates of $32.52 million. With a trailing EPS of -$4.33, Rhythm Pharmaceuticals' earnings are expected to grow next year, from ($4.36) to ($2.63) per share.

RYTM Upcoming Earnings

Rhythm Pharmaceuticals' next earnings date is estimated for Thursday, February 27, 2025, based off prior year's reporting schedules.

Get Rhythm Pharmaceuticals Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rhythm Pharmaceuticals and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

RYTM Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

RYTM Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Rhythm Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20241-$0.77-$0.77-$0.77
Q4 20241-$0.84-$0.84-$0.84
20242-$1.61-$1.61-$1.61
Q1 20251-$0.81-$0.81-$0.81
Q2 20251-$0.76-$0.76-$0.76
Q3 20251-$0.70-$0.70-$0.70
Q4 20251-$0.61-$0.61-$0.61
FY 20254($2.88)($2.88)($2.88)

Rhythm Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks
2/27/2025
(Estimated)
------- 
11/5/2024Q3 2024-$0.80-$0.73+$0.07-$0.73$32.52M$33.20M        
8/6/2024Q2 2024-$0.71-$0.55+$0.16-$0.55$28.79M$29.08M        
5/7/2024Q1 2024-$2.34-$2.35 -$0.01-$2.35$26.90M$26.00M        
2/22/2024Q4 2023-$0.70-$0.70--$0.70$25.38M$24.23M        
11/7/2023Q3 2023-$0.76-$0.76--$0.76$22.18M$22.50M        
8/1/2023Q2 2023-$0.80-$0.82 -$0.02-$0.82$15.03M$19.20M        
5/2/2023Q1 2023-$0.71-$0.92 -$0.21-$0.92$12.12M$11.50M        
3/1/2023Q4 2022-$0.82-$0.75+$0.07-$0.75$7.16M$8.80M        

Rhythm Pharmaceuticals Earnings - Frequently Asked Questions

Rhythm Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 27th, 2025 based off last year's report dates. Learn more on RYTM's earnings history.

In the previous quarter, Rhythm Pharmaceuticals (NASDAQ:RYTM) reported ($0.73) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.80) by $0.07. Learn more on analysts' earnings estimate vs. RYTM's actual earnings.

The conference call for Rhythm Pharmaceuticals's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Rhythm Pharmaceuticals's latest earnings report can be read online.
Read Transcript

Rhythm Pharmaceuticals (NASDAQ:RYTM) has a recorded annual revenue of $77.43 million.

Rhythm Pharmaceuticals (NASDAQ:RYTM) has a recorded net income of -$184.68 million. RYTM has generated -$4.33 earnings per share over the last four quarters.

Rhythm Pharmaceuticals's earnings are expected to grow from ($4.36) per share to ($2.63) per share in the next year.

`

More Earnings Resources from MarketBeat



This page (NASDAQ:RYTM) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners